Celldex Therapeutics, Inc. (CLDX) Stock Analysis

Q: What is the CLDX stock price target?

Take-profit $49.59 (+52.2% upside). Prior stop was $30.30.

Q: What are the risks of investing in CLDX?

Concentration risk — Product: barzolvolimab; Quality below floor (1.7 < 4.0); Quality below floor (1.7 < 4.0); Momentum score 2.5/10 — below 4.5 minimum.

Q: Is CLDX overvalued or undervalued?

Celldex Therapeutics, Inc. trades at a P/E of N/A (forward -6.7). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about CLDX?

22 analysts cover CLDX with a consensus score of 4.1/5. Average price target: $57.

Range Bound setup

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 7 days (2026-05-07). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $32.52: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum.

Celldex Therapeutics is a clinical-stage biopharmaceutical company focused on mast cell biology, developing therapeutic antibodies for severe inflammatory and allergic diseases. Its lead candidate barzolvolimab targets the KIT receptor and is in Phase 3 trials for chronic... Read more

$32.52+52.2% A.UpsideScore 5.0/10#78 of 158 Biotechnology

Stop $30.30Target $49.59(analyst − 13%)A.R:R 4.1:1

Analyst target$57.00+75.3%14 analysts

$49.59our TP

$32.52price

$57.00mean

$90

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Product: barzolvolimab

Quality below floor (1.7 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-6.7

Mkt Cap$2.5B

EV/EBITDA-5.7

Profit Mgn0.0%

ROE-40.6%

Rev Growth-89.7%

Beta1.20

DividendNone

Rating analysts22

Quality Signals

Piotroski F3/9

Options Flow

P/C0.83neutral

IV76%elevated

Max Pain$15-53.9% vs spot

Concentration Risks(10-K Item 1A)

HIGHProductbarzolvolimab
10-K Item 1A: 'Even if we are successful in obtaining regulatory approval for barzolvolimab or one or more of our other drug candidates'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.715%0.26

Growth5.015%0.75

Momentum2.510%0.25

Sentiment8.310%0.83

Insider Activity5.010%0.50

Peer Rank4.110%0.41

Technical Setup5.95%0.30

Risk Profile4.65%0.23

Catalyst2.95%0.14

Overall (Σ contributions)5.01

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

3.3

Current Ratio

5.0

Moat

5.0

Cash-burning: FCF -8126% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Volume

0.0

Obv

1.0

Rsi

5.5

Ma Position

6.0

Volume distribution (falling OBV)Above 200-day MA

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Earnings Timing

5.0

Erm

6.5

Earnings concerns: 0B/4MEarnings in 7 days

GatesMomentum 2.5<4.5EARNINGS PROXIMITY 7d<=7dA.R:R 4.1 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive

RSI

53 · Neutral

↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $28.41Resistance $35.79

Price Targets

$30

$50

A.Upside+52.5%

A.R:R4.1:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.7 < 4.0)

! Momentum score 2.5/10 — below 4.5 minimum

! EARNINGS_PROXIMITY:7d<=7d

Earnings

0/4 beats

Next Earnings2026-05-07 (7d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is CLDX stock a buy right now?

Sell if holding. Engine safety override at $32.52: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $30.30. Score 5.0/10, moderate confidence.

What is the CLDX stock price target?

Take-profit target: $49.59 (+52.2% upside). Prior stop was $30.30. Stop-loss: $30.30.

What are the risks of investing in CLDX?

Concentration risk — Product: barzolvolimab; Quality below floor (1.7 < 4.0).

Is CLDX overvalued or undervalued?

Celldex Therapeutics, Inc. trades at a P/E of N/A (forward -6.7). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about CLDX?

22 analysts cover CLDX with a consensus score of 4.1/5. Average price target: $57.

What does Celldex Therapeutics, Inc. do?Celldex Therapeutics is a clinical-stage biopharmaceutical company focused on mast cell biology, developing therapeutic...